Identifying Outcome Reporting Bias in Randomised Trials on PubMed: Review of Publications and Survey of Authors
Overview
Authors
Affiliations
Objective: To examine the extent and nature of outcome reporting bias in a broad cohort of published randomised trials.
Design: Retrospective review of publications and follow up survey of authors. Cohort All journal articles of randomised trials indexed in PubMed whose primary publication appeared in December 2000.
Main Outcome Measures: Prevalence of incompletely reported outcomes per trial; reasons for not reporting outcomes; association between completeness of reporting and statistical significance.
Results: 519 trials with 553 publications and 10,557 outcomes were identified. Survey responders (response rate 69%) provided information on unreported outcomes but were often unreliable--for 32% of those who denied the existence of such outcomes there was evidence to the contrary in their publications. On average, over 20% of the outcomes measured in a parallel group trial were incompletely reported. Within a trial, such outcomes had a higher odds of being statistically non-significant compared with fully reported outcomes (odds ratio 2.0 (95% confidence interval 1.6 to 2.7) for efficacy outcomes; 1.9 (1.1 to 3.5) for harm outcomes). The most commonly reported reasons for omitting efficacy outcomes included space constraints, lack of clinical importance, and lack of statistical significance.
Conclusions: Incomplete reporting of outcomes within published articles of randomised trials is common and is associated with statistical non-significance. The medical literature therefore represents a selective and biased subset of study outcomes, and trial protocols should be made publicly available.
The role of QI collaboratives in neonatology.
Bapat R, Pearlman S J Perinatol. 2024; .
PMID: 39384615 DOI: 10.1038/s41372-024-02124-w.
Primary outcome reporting in clinical trials for older adults with depression.
Rodrigues M, Oprea A, Johnson K, Dufort A, Sanger N, Ghiassi P BJPsych Open. 2024; 10(2):e60.
PMID: 38450491 PMC: 10951853. DOI: 10.1192/bjo.2023.650.
Kocak B, Keles A, Kose F Diagn Interv Radiol. 2024; 30(5):291-298.
PMID: 38375627 PMC: 11590734. DOI: 10.4274/dir.2024.232604.
Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials.
Srivastava A, Nogueras-Gonzalez G, Geng Y, Singh J, Myers J, Li Y J Immunother Precis Oncol. 2024; 7(1):24-40.
PMID: 38327757 PMC: 10846637. DOI: 10.36401/JIPO-23-14.
Marocolo M, Mota G, Rodrigues A, Leite R, Hohl R, Paixao R Sports Med Int Open. 2024; 8:a21816798.
PMID: 38312926 PMC: 10832574. DOI: 10.1055/a-2181-6798.